Equities research analysts forecast that Biomerica, Inc. (NASDAQ:BMRA) will post sales of $2.85 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Biomerica’s earnings. The lowest sales estimate is $1.95 million and the highest is $3.74 million. Biomerica posted sales of $2.73 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 4.4%. The company is expected to issue its next quarterly earnings results on Tuesday, September 7th.
On average, analysts expect that Biomerica will report full-year sales of $8.99 million for the current year, with estimates ranging from $8.09 million to $9.88 million. For the next fiscal year, analysts anticipate that the business will report sales of $28.14 million, with estimates ranging from $22.99 million to $33.29 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that that provide coverage for Biomerica.
Biomerica (NASDAQ:BMRA) last announced its earnings results on Wednesday, April 14th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.13). Biomerica had a negative return on equity of 45.06% and a negative net margin of 61.55%. The business had revenue of $3.63 million for the quarter, compared to analyst estimates of $2.36 million.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Avidian Wealth Solutions LLC purchased a new position in Biomerica during the first quarter worth about $55,000. Virtu Financial LLC purchased a new position in Biomerica during the fourth quarter worth about $66,000. Victory Capital Management Inc. purchased a new position in Biomerica during the first quarter worth about $94,000. GWM Advisors LLC purchased a new position in Biomerica during the first quarter worth about $122,000. Finally, Squarepoint Ops LLC raised its holdings in Biomerica by 41.0% during the fourth quarter. Squarepoint Ops LLC now owns 26,845 shares of the company’s stock worth $134,000 after purchasing an additional 7,806 shares in the last quarter. 30.41% of the stock is owned by hedge funds and other institutional investors.
Biomerica, Inc, a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations.
Read More: Inverted Yield Curve
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.